FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/07/091961 [Registered on: 29/07/2025] Trial Registered Prospectively
Last Modified On: 29/07/2025
Post Graduate Thesis  Yes 
Type of Trial  Observational 
Type of Study   Cross Sectional Study 
Study Design  Other 
Public Title of Study   Levels of VEGFR2, Dab-2 and FOXM1 in periodontal disease and diabetes 
Scientific Title of Study   Estimation of Vascular endothelial growth factor receptor-2 (VEGFR2), Disabled Homolog-2 (Dab-2) protein and Forkhead Box M1 (FOXM1) levels in saliva and serum in generalized periodontitis patients with and without Type 2 Diabetes Mellitus (T2DM) 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Aparna Rajesh 
Designation  Post graduate 
Affiliation  The Oxford Dental College, Bangalore 
Address  Department of Periodontology, Room no.3, The Oxford Dental College, 10th milestone, Bommanahalli, Hosur Road, Bengaluru- 560068

Bangalore
KARNATAKA
560068
India 
Phone  8660025773  
Fax    
Email  aparnatrajesh@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Ashish S Nichani 
Designation  Professor 
Affiliation  The Oxford Dental College 
Address  Department of Periodontology, Room no.3, The Oxford Dental College, 10th milestone, Bommanahalli, Hosur Road, Bengaluru- 560068

Bangalore
KARNATAKA
560068
India 
Phone  9845252203  
Fax    
Email  nichaniashish@hotmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Ashish S Nichani 
Designation  Professor 
Affiliation  The Oxford Dental College 
Address  Department of Periodontology, Room no.3, The Oxford Dental College, 10th milestone, Bommanahalli, Hosur Road, Bengaluru- 560068

Bangalore
KARNATAKA
560068
India 
Phone  9845252203  
Fax    
Email  nichaniashish@hotmail.com  
 
Source of Monetary or Material Support  
The Oxford Dental College, Department of Periodontology, Room no.3, 10th milestone, Bommanahalli, Hosur Road, Bengaluru- 560068 
 
Primary Sponsor  
Name  Dr Aparna Rajesh 
Address  Department of Periodontology, Room no.3, The Oxford Dental College, 10th milestone, Bommanahalli, Hosur Road, Bengaluru- 560068 Karnataka Bangalore KARNATAKA 560068 India 
Type of Sponsor  Other [Self funded] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Aparna Rajesh  The Oxford Dental College, Bangalore  Department of Periodontology, Room no.3, The Oxford Dental College, 10th milestone, Bommanahalli, Hosur Road, Bengaluru- 560068
Bangalore
KARNATAKA 
8660025773

aparnatrajesh@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee The Oxford Dental College  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: E119||Type 2 diabetes mellitus without complications,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  NIL  NIL 
 
Inclusion Criteria  
Age From  35.00 Year(s)
Age To  65.00 Year(s)
Gender  Both 
Details  1. Patients who have not received any periodontal treatment in the previous six months.
2. Patients diagnosed with T2DM as per American Diabetes Association criteria (2019).
3. Patients with a diagnosis of generalized periodontitis as per World Workshop Classification criteria (2017).  
 
ExclusionCriteria 
Details  1. Smokers and alcoholics.
2. Patients with systemic diseases like hypertension, cardiovascular diseases, rheumatoid
arthritis, tumors, autoimmune diseases and renal diseases.
3. Pregnant and lactating females.
4. Any other systemic disease which can alter the course of periodontal disease.
5. Patients on medications like anti-inflammatory drugs, antibiotics and anti-epileptic drugs in
the past 6 months.
6. Post-menopausal women.  
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
To evaluate serum and salivary levels of Vascular endothelial growth factor receptor 2, Disabled homolog-2 protein and Forkhead Box M1 in periodontitis and T2DM patients at baseline  Baseline 
 
Secondary Outcome  
Outcome  TimePoints 
To explore correlation of Vascular endothelial growth factor receptor 2 with Disabled homolog-2 protein & Forkhead Box M1 & clinical, biochemical & demographic parameters at baseline  Baseline 
 
Target Sample Size   Total Sample Size="80"
Sample Size from India="80" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   01/10/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Periodontal disease is one of the major problems encountered in patients with Type 2 diabetes mellitus (T2DM) which in turn is an important and independent risk factor for the development of periodontitis. While periodontitis represents a distant source of low-grade systemic inflammation and impaired metabolic control, on the other hand, microangiopathy and an increased angiogenic response, typical of T2DM, are correlated to the progression of periodontitis. Angiogenesis is also thought to be an essential process in the development of both these chronic inflammatory diseases.

Vascular endothelial growth factor (VEGF), a 45-kd homodimeric pro-inflammatory glycoprotein is a critical angiogenic factor that signals through VEGF receptors (VEGFRs). VEGF receptor 2 (VEGFR2) potentiates angiogenesis more potently than other VEGFRs. In diabetic conditions, there is a decrease in VEGF-induced phosphorylation of VEGFR2 and downstream signaling, leading to impaired angiogenesis. VEGF and VEGFR2 overexpression, as well as the great proliferation rate of endothelial cells observed in periodontitis suggest that angiogenesis in case of periodontal lesions is dependent on VEGF expression.

Disabled Homolog 2 (Dab2) is a highly conserved adaptor protein widely expressed in various tissues and primarily functions as a cytosolic, clathrin and cargo binding adaptor protein, with a pivotal role in endocytosis. Dab2 plays a direct role in regulating VEGF signalling in endothelial cells (ECs). It modulates EC migration and differentiation through a process named endothelial-to-mesenchymal transition (EndMT), which plays a key role in angiogenesis. Upregulation of Dab2 gene is seen in circulating lymphocytes and monocytes of periodontitis patients. Hyperglycemic ECs exhibit downregulation of Dab2 mRNA and protein levels, along with reduced expression of genes involved in cellular metabolism, growth, and proliferation.

Forkhead box protein M1 (FOXM1), belongs to the Forkhead family of transcriptional factors, is highly conserved & exerts regulatory control over Dab2 expression in endothelial cells during angiogenesis. Loss of FOXM1 is associated with upregulation of RANKL/OPG ratio. It also plays a crucial role in diabetes related cellular functions via beta cell proliferation, essential for pancreatic repair and insulin secretion.

To the best of our knowledge the roles of VEGFR2, Dab2 and FOXM1 have not been investigated together in patients with periodontitis and diabetes. Hence, the aim of this study is to evaluate the salivary and serum levels of VEGFR2, Dab2 and FOXM1 in patients with generalized periodontitis and type 2 diabetes mellitus.

 
Close